2023 was a troublesome 12 months for your biopharma business, with a number of corporations downsizing and restructuring their workforces to remain afloat. You will discover indications of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace from the latter Element of 2023 and https://sites.google.com/view/bio-sites/blog